|
In situ Formation and NNNT increase over time
|
|
6
|
309
|
October 7, 2026
|
|
Theoretical evaluation of NDSRIs
|
|
13
|
655
|
September 25, 2026
|
|
MEGLUMINE (Methylglucamine)
|
|
31
|
4565
|
July 20, 2026
|
|
Process-dependent N-nitroso-ketamine formation during ketamine active pharmaceutical ingredient manufacturing: part I impact of process design, solvent selection, and activated carbon-Pub
|
|
1
|
187
|
July 15, 2026
|
|
Peptide Synthesis - Does anyone have experience with potential Nitrosamine impurities coming from solid phase synthesis?
|
|
2
|
323
|
July 6, 2026
|
|
Analytical Challenges in Quantifier Ion Selection Due to Mass Error Variability
|
|
7
|
384
|
July 2, 2026
|
|
Recrystallization can stop nitrosamine formation in ranitidine hydrochloride - PUB
|
|
1
|
274
|
June 24, 2026
|
|
Finasteride NDSRI
|
|
2
|
200
|
June 15, 2026
|
|
Understanding In Vitro Nitrosamine Formation During Sample Preparation
|
|
4
|
348
|
June 1, 2026
|
|
Nitrite in Amines
|
|
14
|
1184
|
May 21, 2026
|
|
Strategies for Mitigating In-Source Fragmentation in NDSRI Analysis using LC-MS
|
|
4
|
3077
|
May 20, 2026
|
|
N-Nitrosoatorvastatin and applicable potency category 4 or 5
|
|
2
|
172
|
March 20, 2026
|
|
EMA proposes GMP update to EudraLex to address nitrosamine impurities
|
|
14
|
1344
|
February 20, 2026
|
|
Available Tools for Prediction of Potential Degradation Products from Nitrosation Reactions
|
|
4
|
348
|
February 4, 2026
|
|
N-nitroso-rivaroxaban amide
|
|
7
|
2194
|
February 4, 2026
|
|
Limit of Common or Small Nitrosamine Impurities in RSM irrespective of any particular MDD
|
|
9
|
559
|
January 21, 2026
|
|
How to determine the AI limit value and LOQ when MDD is less than 880mg?
|
|
1
|
243
|
January 20, 2026
|
|
How to Establish MDD for Creams and Ophthalmic Solutions
|
|
4
|
444
|
January 8, 2026
|
|
Nitrosamine Purge Factor Calculation
|
|
1
|
556
|
December 30, 2025
|
|
Nitrosamines in macrocyclic antibiotics
|
|
2
|
306
|
December 10, 2025
|
|
Levetiracetam_Presence of Nitrosamines
|
|
0
|
168
|
December 9, 2025
|
|
FDA Approves Reformulated Ranitidine - Nitrosamine Impurities - NDMA
|
|
3
|
661
|
November 27, 2025
|
|
👨💻 Quantitative Analysis of N-Nitrosodimethylamine (NDMA), N-Nitrosodiethylamine (NDEA), and -Nitroso-N-methyl-4-aminobutyric acid (NMBA) in Losartan Potassium Tablets by Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry
|
|
1
|
483
|
September 24, 2025
|
|
Nitrosamine CPCA
|
|
5
|
545
|
September 18, 2025
|
|
👨💻 Quantitative Analysis of NDMA, N-Nitroso-l-ephedrine and N-Nitroso-pseudoephedrine in Pseudoephedrine Hydrochloride by HPLC-Tandem MS
|
|
2
|
832
|
August 28, 2025
|
|
Low recovery factor & Validation Issue
|
|
11
|
820
|
July 22, 2025
|
|
CMO Nitrosamine Risk Assessment
|
|
7
|
582
|
June 27, 2025
|
|
Nitrosamines in Carbamazepine?
|
|
5
|
1047
|
June 27, 2025
|
|
👨💻 Quantitative Analysis of N-Nitrosodimethylamine in Metformin HCl by Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry
|
|
3
|
873
|
June 3, 2025
|
|
Separation of Nitrosamines and Ranitidine
|
|
3
|
305
|
May 27, 2025
|